Reversible disulfide formation of the glutamate carboxypeptidase II inhibitor E2072 results in prolonged systemic exposures in vivo

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2315-2323

  Rais, Rana ^a   Hoover, Randall ^b   Wozniak, Krystyna ^a,b   Rudek, Michelle A ^a   Tsukamoto, Takashi ^a,b   Alt, Jesse ^a,b   Rojas, Camilo ^a,b   Slusher, Barbara S ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 2 MERCAPTOETHYL)BIPHENYL 2,3' DICARBOXYLIC ACID; [(3 2 MERCAPTOETHYL)BIPHENYL 2,3' DICARBOXYLIC ACID] HOMODISULFIDE; E 2072; PEPTIDE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; MALE; NONHUMAN; PAIN; PRIMATE; PRIORITY JOURNAL; RAT; RODENT; SCIATIC NERVE INJURY; SINGLE DRUG DOSE; SPECIES DIFFERENCE;

ANIMALS; BENZOATES; BIOLOGICAL AVAILABILITY; DISULFIDES; DOGS; GLUTAMATE CARBOXYPEPTIDASE II; HALF-LIFE; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICROSOMES, LIVER; PAIN; RATS; RATS, SPRAGUE-DAWLEY; SULFHYDRYL COMPOUNDS; TISSUE DISTRIBUTION;

PRIMATES; RATTUS; RODENTIA;

EID: 84869143515     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046821     Document Type: Article

References (41)

1. Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, and Teramura T (2009) A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308-316.
2. Bařinka C, Rojas C, Slusher B, and Pomper M (2012) Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 19:856-870.
3. Bennett GJ and Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107.
4. Bourke CE, Miners JO, and Birkett DJ (1984) Reversible metabolism of D-penicillamine in the rat. Drug Metab Dispos 12:798-799.
5. Bungay PJ, Tweedy S, Howe DC, Gibson KR, Jones HM, and Mount NM (2011) Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist. Drug Metab Dispos 39:1396-1405.
6. Carozzi VA, Chiorazzi A, Canta A, Lapidus RG, Slusher BS, Wozniak KM, and Cavaletti G (2010) Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res 17:380-391.
7. Chen SR, Wozniak KM, Slusher BS, and Pan HL (2002) Effect of 2-(phosphono-methyl)- pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther 300:662-667.
8. Drummer OH and Jarrott B (1984) Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat. Biochem Pharmacol 33:3567-3571.
9. Drummer OH, Thompson J, Hooper R, and Jarrott B (1985) Effect of probenecid on the disposition of captopril and captopril dimer in the rat. Biochem Pharmacol 34:3347-3351.
10. Fukuda H, Ohashi R, Tsuda-Tsukimoto M, and Tamai I (2008) Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Drug Metab Dispos 36:1275-1282.
11. Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ, et al. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 100:9554-9559.
12. Giustarini D, Dalle-Donne I, Milzani A, and Rossi R (2011) Detection of glutathione in whole blood after stabilization with N-ethylmaleimide. Anal Biochem 415:81-83.
13. Harada C, Harada T, Slusher BS, Yoshida K, Matsuda H, and Wada K (2000) N-acetylated-alpha-linked-acidic dipeptidase inhibitor has a neuroprotective effect on mouse retinal ganglion cells after pressure-induced ischemia. Neurosci Lett 292:134-136.
14. Hargreaves K, Dubner R, Brown F, Flores C, and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
15. Horiuchi M, Takashina H, Iwatani T, and Iso T (1985) [Study on metabolism of the dithiol compound. I. Isolation and identification of metabolites of N-(2-mercapto-2-methylpro-panoyl)- L- cysteine (SA96) in the blood and urine of the rat]. Yakugaku Zasshi 105:665-670.
16. Jackson PF, Tays KL, Maclin KM, Ko YS, Li W, Vitharana D, Tsukamoto T, Stoermer D, Lu XC, Wozniak K, et al. (2001) Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem 44:4170-4175.
17. Jayaraman R, Pilla Reddy V, Pasha MK, Wang H, Sangthongpitag K, Yeo P, Hu CY, Wu X, Xin L, Goh E, et al. (2011) Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos 39:2219-2232.
18. Luszczki JJ, Mohamed M, and Czuczwar SJ (2006) 2-phosphonomethyl- pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice. Eur J Pharmacol 531:66-73.
19. Majer P, Jackson PF, Delahanty G, Grella BS, Ko YS, Li W, Liu Q, Maclin KM, Poláková J, Shaffer KA, et al. (2003) Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 46:1989-1996.
20. Marmiroli P, Slusher B, and Cavaletti G (2012) Tissue distribution of glutamate carboxypeptidase II (GCPII) with a focus on the central and peripheral nervous system. Curr Med Chem 19:1277-1281.
21. Neale JH, Olszewski RT, Gehl LM, Wroblewska B, and Bzdega T (2005) The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 26:477-484.
22. Neale JH, Olszewski RT, Zuo D, Janczura KJ, Profaci CP, Lavin KM, Madore JC, and Bzdega T (2011) Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem 118:490-498.
23. Pilkington AE and Waring RH (1988) The metabolism and disposition of D-penicillamine in the DA-strain rat. Eur J Drug Metab Pharmacokinet 13:99-104.
24. Rahn KA, Slusher BS, and Kaplin AI (2012) Glutamate in CNS neurodegeneration and cognition and its regulation by GCPII inhibition. Curr Med Chem 19:1335-1345.
25. Slusher BS, Robinson MB, Tsai G, Simmons ML, Richards SS, and Coyle JT (1990) Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization. J Biol Chem 265:21297-21301.
26. Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XC, et al. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5:1396-1402.
27. Spiga O, Summa D, Cirri S, Bernini A, Venditti V, De Chiara M, Priora R, Frosali S, Margaritis A, Di Giuseppe D, et al. (2011) A structurally driven analysis of thiol reactivity in mammalian albumins. Biopolymers 95:278-285.
28. Stoermer D, Vitharana D, Hin N, Delahanty G, Duvall B, Ferraris DV, Grella BS, Hoover R, Rojas C, Shanholtz MK, et al. (2012) Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds. J Med Chem 55:5922-5932.
29. Tsukamoto T, Flanary JM, Rojas C, Slusher BS, Valiaeva N, and Coward JK (2002) Phosphonate and phosphinate analogues of N-acylated gamma- glutamylglutamate. potent inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett 12:2189-2192.
30. van der Post JP, de Visser SJ, de Kam ML, Woelfler M, Hilt DC, Vornov J, Burak ES, Bortey E, Slusher BS, Limsakun T, et al. (2005) The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 60:128-136.
31. Witkin JM, Gasior M, Schad C, Zapata A, Shippenberg T, Hartman T, and Slusher BS (2002) NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology 43:348-356.
32. Worland PJ, Drummer OH, and Jarrott B (1984) Gastric and intestinal absorption of captopril in acutely and chronically treated rats: comparison with salicylic acid. J Pharm Sci 73:1755-1758.
33. Wozniak KM, Rojas C, Wu Y, and Slusher BS (2012) The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. Curr Med Chem 19:1323-1334.
34. Xi ZX, Kiyatkin M, Li X, Peng XQ, Wiggins A, Spiller K, Li J, and Gardner EL (2010a) N-Acetylaspartylglutamate (NAAG) inhibits intravenous cocaine self-administration and cocaine-enhanced brain-stimulation reward in rats. Neuropharmacology 58:304-313.
35. Xi ZX, Li X, Peng XQ, Li J, Chun L, Gardner EL, Thomas AG, Slusher BS, and Ashby CR Jr (2010b) Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem 112:564-576.
36. Yamamoto T, Nozaki-Taguchi N, and Sakashita Y (2001a) Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res 909:138-144.
37. Yamamoto T, Nozaki-Taguchi N, Sakashita Y, and Inagaki T (2001b) Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 102:473-479.
38. Yamauchi H, Morikawa K, Kuwano M, Hikida M, Fujimura K, Horiuchi M, Uemura O, and Iso T (1985) [Pharmacological studies of N-(2-mercapto-2- methylpropionyl)-L- cysteine (SA 96). VI. Effects on vitamin B6, metals and skin collagen in rats]. Nihon Yakurigaku Zasshi 86:25-33.
39. Yeung JH, Breckenridge AM, and Park BK (1983) Drug protein conjugates-VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates. Biochem Pharmacol 32:3619-3625.
40. Zhang W, Murakawa Y, Wozniak KM, Slusher B, and Sima AA (2006) The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 247:217-223.
41. Zhang W, Slusher B, Murakawa Y, Wozniak KM, Tsukamoto T, Jackson PF, and Sima AA (2002) GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 194:21-28.